Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants.
Hill BT, Bolwell BJ, Rybicki L, Dean R, Kalaycio M, Pohlman B, Tench S, Sobecks R, Andresen S, Copelan E. Hill BT, et al. Among authors: copelan e. Biol Blood Marrow Transplant. 2010 Dec;16(12):1738-46. doi: 10.1016/j.bbmt.2010.06.009. Epub 2010 Jun 14. Biol Blood Marrow Transplant. 2010. PMID: 20558313 Free article.
Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: predictors and clinical relevance.
Pecora AL, Lazarus HM, Jennis AA, Preti RA, Goldberg SL, Rowley SD, Cantwell S, Cooper BW, Copelan EA, Herzig RH, Meagher R, Kennedy MJ, Akard LR, Jansen J, Ross A, Prilutskaya M, Glassco J, Kahn D, Moss TJ. Pecora AL, et al. Biol Blood Marrow Transplant. 2002;8(10):536-43. doi: 10.1053/bbmt.2002.v8.pm12434948. Biol Blood Marrow Transplant. 2002. PMID: 12434948 Free article.
Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission.
Litzow MR, Pérez WS, Klein JP, Bolwell BJ, Camitta B, Copelan EA, Gale RP, Giralt SA, Keating A, Lazarus HM, Marks DI, McCarthy PL, Miller CB, Milone G, Prentice HG, Russell JA, Schultz KR, Trigg ME, Weisdorf DJ, Horowitz MM. Litzow MR, et al. Among authors: copelan ea. Br J Haematol. 2002 Dec;119(4):1115-24. doi: 10.1046/j.1365-2141.2002.03973.x. Br J Haematol. 2002. PMID: 12472596 Free article.
Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Williams CB, Day SD, Reed MD, Copelan EA, Bechtel T, Leather HL, Wingard JR, Abbott BL, Abhyankar S, McGuirk JP. Williams CB, et al. Biol Blood Marrow Transplant. 2004 Sep;10(9):614-23. doi: 10.1016/j.bbmt.2004.05.010. Biol Blood Marrow Transplant. 2004. PMID: 15319773 Free article. Clinical Trial.
High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.
Farag SS, Bolwell BJ, Elder PJ, Kalaycio M, Lin T, Pohlman B, Penza S, Marcucci G, Blum W, Sobecks R, Avalos BR, Byrd JC, Copelan E. Farag SS, et al. Among authors: copelan e. Bone Marrow Transplant. 2005 Apr;35(7):653-61. doi: 10.1038/sj.bmt.1704867. Bone Marrow Transplant. 2005. PMID: 15711571 Clinical Trial.
251 results